Pulse announces findings from its CellFX nsPFA 360 cardiac catheter study

Pulse Biosciences announced that its nsPFA technology will be featured in a podium presentation at the 29th Annual AF Symposium in Boston, Massachusetts, on February 2… The session will include a presentation on the latest developments in Nanosecond Pulsed Field nsPFA technology, specifically highlighting the preliminary findings from the Company’s CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study. Dr. Petr Neuil, Chief of Cardiology at Na Homolce Hospital, Prague and Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital, New York will provide an overview of their experience with the CellFX nsPFA 360 Cardiac Catheter and discuss the potential clinical implications and impact on the treatment of atrial fibrillation. “I look forward to presenting one of our initial cases with this promising technology at the AF Symposium and am honored to be part of the team to perform the first-in-human procedures with the CellFX nsPFA 360 Cardiac Catheter,” said Dr. Vivek Reddy. “The circumferential footprint and flexible structure of the 360 nsPFA catheter has been extremely fast and versatile in these initial procedures, setting it apart from many other PFA catheters. We look forward to completing enrollment in this study to fully assess the safety and durability of this next generation PFA technology.”